Yong, Jie Ning
Ng, Cheng Han
Lee, Chloe Wen-Min
Chan, Yu Yi
Tang, Ansel Shao Pin
Teng, Margaret
Tan, Darren Jun Hao
Lim, Wen Hui
Quek, Jingxuan
Xiao, Jieling
Chin, Yip Han
Foo, Roger
Chan, Mark
Lin, Weiqin
Noureddin, Mazen
Siddiqui, Mohammad Shadab
Muthiah, Mark D. http://orcid.org/0000-0002-9724-4743
Sanyal, Arun
Chew, Nicholas W. S. http://orcid.org/0000-0002-0640-0430
Article History
Received: 12 January 2022
Accepted: 11 February 2022
First Online: 23 March 2022
Declarations
:
: Arun J. Sanyal: Dr Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect and Galmed. He has served as a consultant to Astra Zeneca, Nitto Denko, Enyo, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck, Valeant, Boehringer-Ingelheim, Lilly, Hemoshear, Zafgen, Novartis, Novo Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Affimune, Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Norvatis. He receives royalties from Elsevier and UptoDate. Mazen Noureddin: has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Terns, Siemens and Roche diagnostic; MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and Zydus; MN is a minor shareholder or has stocks in Anaetos, Rivus Pharma and Viking. All other authors have no conflicts of interests.